INTRODUCTION

53
The prevention of infectious bronchitis (IB) in chickens is achieved through the use of 54 live and inactivated vaccines, which provide protection against virulent field IB viruses in the 55 event of an exposure. Despite these preventative measures, outbreaks of IB frequently occur 56 in many poultry producing countries (1) (2) (3) . This is probably due to the emergence of new 57 variants of infectious bronchitis virus (IBV) (1-5). For the successful protection of chickens 58 against infection, it is essential to identify the prevalent genotypes in the region and to 59 determine the cross-protective potential of available vaccines and optimise strategic 60 vaccination programmes.
61
IB was first described in the USA during the 1930s and was identified in the UK in 62 1948. Thereafter, many IBV variants were isolated from Europe, significantly a variant called 63 793B that emerged in the 1990s (6). Later, IBV QX was first identified in China (7) before 64 spreading to Europe (8) . Another IBV genotype, Q1, genetically and serologically distinct 65 from the classical IBVs, was also reported in China (9), the Middle East (10) and Europe chicks against a subsequent IBV challenge (15, 18) . During the course of experimental viral 80 infection, Kotani et al (2000) showed that the clearance of the IBV from the tracheal mucosa 81 occurred at an early phase of the infection and CTLs at the tracheal mucosa were proposed to 82 be involved in this clearance (19) . To date, there is no information available on the tracheal 
MATERIALS AND METHODS
98
Birds
99
One hundred twenty broiler chicks, aged 1-day-old, were obtained from a commercial 100 hatchery. Birds were allowed ad libitum access to feed and drinking water. All procedures 101 were undertaken according to the UK legislation on the use of animals for experiments as 102 permitted under the project license PPL 40/3723, which was approved by the University of
103
Liverpool ethical review committee.
104
Challenge virus
105
The virulent Q1 isolate used in this study was kindly provided by Merial Animal Health.
106
PCR confirmed that the allantoic fluid, from eggs used to propagate the virus, was free of 107 Newcastle disease, avian influenza, infectious bursal disease, infectious laryngotracheitis and 108 avian metapneumoviruses. Q1 IBV was also free of bacterial or fungal contaminants. The 109 virus was titrated in the chicken tracheal organ culture (TOC) as described before and 110 expressed in 50% (median) ciliostatic doses (CD 50 )/ml (21). live IBV CR88 (GALLIVAC ® IB88) vaccines were mixed together in 100 ml of SW.
117
Immediately after preparation, the vaccines and SW were kept in a cold box (at 0°C CT-4; 0.5 mg/ml) and CD8a (clone CT-8; 0.5 mg/ml) at 1:1000, and to chicken IgA (clone A- for microscopic evaluation, the scores attributed according to histopathological severity and 210 determined by recommendations described previously (28, 29).
211
Real time RT-PCR (RT-qPCR)
212
Total RNA extractions from the tracheas and kidneys, collected from the challenged 
RESULTS
235
Systemic humoral immune response
On the day of vaccination, the mean of maternally derived anti-IBV antibody titre was
238
1750±203. Subsequently, the antibody levels in all three groups declined to below cut-off 239 point (396) by 14 doa. After the booster vaccination with the CR88 at 14 doa, a significant 240 increase in the antibody titres till 28 doa was observed in groups I and II, as shown in Fig. 1 .
241
On these time points, the levels of antibodies were not significantly different between the 242 vaccinated groups (P<0.05). After 14 doa though, the antibody titres in group III was always 243 less than the cut-off value of 396 in this assay.
244
HI test
245
The level of serotype specific antibodies against homologous and heterologous
246
antigens was evaluated by a HI test (Table 2 ). The HI antibody response against all the 247 antigens used showed no significant difference (P<0.05) between the groups from 0 to7 doa.
248
However, a lower antibody response was obtained in all groups when the antigen used in the
249
HI test was heterologous (Q1) to the viruses used in the vaccination. On 14 doa, the mean HI 250 antibody titre to the M41 was significantly higher (P<0.05) in group II than group I and III. was observed at any doa (Fig. 2b) . IgA levels in tears and tracheal washes of both vaccinated 269 groups were significantly higher than the levels from the unvaccinated control group.
270
Systemic cell-mediated immune response 271
CD4+:CD8+ ratio in peripheral blood
272
Flow cytometry results showed that at 7 doa, the CD4+:CD8+ ratios were slightly 273 higher in both vaccinated groups compared to that of the non-vaccinated group, though there 274 was no significant difference (P<0.05) between the CD4+:CD8+ ratios of the vaccinated and 275 non-vaccinated groups observed up to 14 doa (Fig. 3) . After the booster vaccination with the 276 CR88 at 14 doa, the ratio of CD4+:CD8+ on 21 doa showed slight increase in both vaccinated 277 groups, being significantly higher (P<0.05) in group I compared to that of group II and III.
278
At 28 doa, the ratio was significantly higher (P<0.05) in group II compared to groups I and
279
III.
280
Mucosal cell-mediated immune responses in the trachea
281
The kinetics of CD4+, CD8+ and IgA-bearing B lymphocytes in the trachea were 282 studied by IHC (Fig. 4) . and tumour necrosis factor-α (58). Therefore, we may speculate that the group II's higher 
452
The results of RT-qPCR and scores of histopathology in the kidneys showed that the 453 damage caused by the Q1 was higher in group I than II, and showed no significant difference 
CONCLUSIONS
463
Chicks vaccinated with H120 and CR88 at day-old, followed by CR88 at 14 doa, showed 464 significantly higher CD8+ responses in the trachea and higher lachrymal IgA levels compared 465 to those vaccinated with H120 alone. In terms of ciliary protection against Q1, though both 466 vaccinated groups were protected, the combined vaccination of H120 and CR88 of day-old 467 chicks, followed by CR88 at 14 doa, showed higher ciliary protection and less RNA load in 
